molecular formula C13H18O2 B1670340 (S)-(+)-Ibuprofen CAS No. 51146-56-6

(S)-(+)-Ibuprofen

Cat. No.: B1670340
CAS No.: 51146-56-6
M. Wt: 206.28 g/mol
InChI Key: HEFNNWSXXWATRW-JTQLQIEISA-N
Attention: For research use only. Not for human or veterinary use.
In Stock
  • Click on QUICK INQUIRY to receive a quote from our team of experts.
  • With the quality product at a COMPETITIVE price, you can focus more on your research.

Description

(S)-(+)-Ibuprofen, also known as dexibuprofen, is the pharmacologically active enantiomer of racemic ibuprofen, a non-steroidal anti-inflammatory drug (NSAID). It inhibits cyclooxygenase (COX) enzymes, particularly COX-2 (IC50 = 1.1 μM), with higher potency than COX-1 (IC50 = 2.9 μM) . Unlike the racemic mixture, which contains equal parts (R)-(-)- and this compound, the (S)-enantiomer is solely responsible for therapeutic effects due to its stereospecific binding to COX . Approximately 50–60% of the (R)-enantiomer undergoes metabolic inversion to this compound via 2-arylpropionyl-CoA epimerase in vivo, explaining the efficacy of racemic formulations . This compound is commercially available in tablets, gels, and intravenous formulations, with doses typically 25–50% lower than racemic equivalents for comparable efficacy .

Preparation Methods

Synthetic Routes and Reaction Conditions

The preparation of dexibuprofen involves the resolution of racemic ibuprofen into its enantiomers. One method includes adding toluene into a reaction kettle, followed by ibuprofen and meglumine, heating to 76-80°C, and maintaining the temperature for over 0.5 hours. The material is then transferred into an amine salt crystallization kettle, followed by the addition of purified water, cooling for crystallization, and performing centrifugal separation, washing, and drying to obtain dexibuprofen meglumine salt .

Industrial Production Methods

Industrial production of dexibuprofen can involve the use of nanotechnology. For instance, dexibuprofen nanocrystals can be fabricated using a microchannel fluidic reactor. This method involves mixing drug and polymer solutions in the reactor, followed by decanting the nanosuspension into a vial containing the polymer solution. The process parameters such as inlet angle, antisolvent and solvent flow rates, mixing time, and drug concentration are optimized to produce stable nanocrystals .

Chemical Reactions Analysis

(S)-(+)-Ibuprofen undergoes various chemical reactions, including:

    Oxidation: this compound can be oxidized under specific conditions, leading to the formation of various oxidation products.

    Reduction: Reduction reactions can convert dexibuprofen into its reduced forms.

    Substitution: this compound can undergo substitution reactions where one functional group is replaced by another. Common reagents and conditions used in these reactions include oxidizing agents like potassium permanganate, reducing agents like lithium aluminum hydride, and various catalysts. .

Scientific Research Applications

Pain Management

(S)-(+)-Ibuprofen is extensively employed for managing various types of pain, including:

  • Acute Pain : Effective in treating postoperative pain and acute injuries.
  • Chronic Pain : Used in conditions such as osteoarthritis and rheumatoid arthritis.
  • Gout : Demonstrated efficacy in alleviating symptoms during acute gout attacks, with studies showing rapid improvement in patients treated with high doses (2400 mg) .

Anti-Inflammatory Uses

The anti-inflammatory effects of this compound are attributed to its ability to inhibit cyclooxygenase enzymes (COX-1 and COX-2), which play a crucial role in the inflammatory response. Specific applications include:

  • Pericarditis : Recommended as a treatment option for acute pericarditis, showing effectiveness comparable to aspirin .
  • Inflammatory Conditions : Utilized in various inflammatory disorders due to its ability to reduce prostaglandin synthesis .

Antipyretic Effects

This compound is commonly used to reduce fever. In clinical studies, it has been shown to be more effective than acetaminophen in lowering temperatures associated with infections such as uncomplicated falciparum malaria .

Cancer Treatment Potential

Recent research indicates that this compound may have anticancer properties. Studies suggest its potential role in:

  • Colorectal Cancer Prevention : Some evidence supports its use in reducing the incidence of colorectal cancer .
  • Chemotherapy Resistance : Investigations are ongoing regarding its ability to enhance the efficacy of chemotherapy agents by mitigating resistance mechanisms .

Neuropathic Pain Management

Research has indicated that this compound may affect endocannabinoid metabolism, potentially offering benefits in neuropathic pain settings. A study found that it inhibits the metabolism of endocannabinoids more effectively than arachidonic acid metabolism, suggesting a unique analgesic mechanism .

Adverse Reactions and Safety Profile

While generally safe when used appropriately, this compound can cause adverse reactions, including:

  • Stevens-Johnson Syndrome : A rare but severe skin reaction linked to ibuprofen use has been documented .
  • Liver Injury : Case studies have reported instances of drug-induced liver injury associated with ibuprofen, emphasizing the need for careful monitoring .

Comprehensive Data Table

ApplicationDescriptionReferences
Pain ManagementEffective for acute and chronic pain management
Anti-inflammatory UsesReduces inflammation in conditions like arthritis and pericarditis
Antipyretic EffectsReduces fever more effectively than acetaminophen
Cancer Treatment PotentialMay prevent colorectal cancer and enhance chemotherapy efficacy
Neuropathic PainInhibits endocannabinoid metabolism; potential analgesic effects
Adverse ReactionsRisk of Stevens-Johnson syndrome and liver injury

Case Studies

Several case studies illustrate the diverse applications and implications of this compound:

  • Case of Acute Gout : A study highlighted rapid symptom resolution in patients treated with high-dose ibuprofen during gout attacks, demonstrating its effectiveness as a first-line therapy .
  • Stevens-Johnson Syndrome : A case involving a child who developed severe skin reactions after ibuprofen use underscores the importance of monitoring for adverse drug reactions .
  • Liver Injury Case Study : Documented instances of ibuprofen-induced liver injury call attention to the need for awareness regarding potential hepatotoxicity associated with NSAIDs .

Mechanism of Action

(S)-(+)-Ibuprofen exerts its effects by inhibiting the enzyme cyclooxygenase-2 (COX-2), which is involved in the synthesis of prostaglandins. Prostaglandins are lipid compounds that play a key role in inflammation, pain, and fever. By inhibiting COX-2, dexibuprofen reduces the production of prostaglandins, leading to decreased inflammation and pain .

Comparison with Similar Compounds

Comparison with Racemic Ibuprofen

Pharmacological Activity

Parameter (S)-(+)-Ibuprofen Racemic Ibuprofen References
COX-1 Inhibition IC50 = 2.9 μM IC50 = 4.5 μM*
COX-2 Inhibition IC50 = 1.1 μM IC50 = 2.3 μM*
Active Enantiomer 100% 50% (R) + 50% (S)

*Calculated based on racemic mixture’s composition.

This compound exhibits 2–3 times greater COX-2 selectivity than the racemate, enhancing anti-inflammatory efficacy . Clinical studies demonstrate that 200 mg this compound provides equivalent or superior pain relief to 400 mg racemic ibuprofen in dental and osteoarthritis pain models .

Pharmacokinetics

  • Metabolic Inversion : Racemic ibuprofen’s (R)-enantiomer undergoes 50–60% conversion to this compound, resulting in ~75% total active enantiomer bioavailability .
  • Plasma Concentrations : Pure this compound achieves higher plasma levels of the active form compared to racemic administration, reducing interpatient variability .
  • Half-life : Both forms share similar half-lives (~2 hours), but this compound avoids the metabolic burden of inverting (R)-enantiomer .

Comparison with Other NSAIDs

Mefenamic Acid

Parameter This compound Mefenamic Acid References
COX-1 Selectivity Moderate High
Analgesic Duration 4–6 hours 6–8 hours
GI Toxicity Lower Higher

Mefenamic acid, a fenamate NSAID, exhibits stronger COX-1 inhibition, increasing GI ulcer risk. This compound’s COX-2 preference offers a safer profile for chronic use .

Naproxen

Parameter This compound Naproxen References
Half-life 2 hours 12–17 hours
Cardiovascular Risk Low Low
Dosing Frequency 3–4 times/day 2 times/day

Naproxen’s prolonged half-life allows less frequent dosing but increases accumulation risk in renal impairment. This compound’s rapid clearance suits acute pain management .

Formulation Advantages

This compound salts, such as (S)-(+)-lysinate and piperazine di-ium bis(S-ibuprofenate), improve aqueous solubility (e.g., 100 mM in DMSO) and bioavailability . These formulations enable intravenous administration, bypassing first-pass metabolism and achieving faster onset .

Clinical and Economic Considerations

  • Cost-Effectiveness : Racemic ibuprofen remains cheaper due to simpler synthesis, but this compound’s lower effective dose reduces long-term toxicity costs .
  • Dose Equivalence : 200–300 mg this compound ≈ 400–600 mg racemic ibuprofen .

Biological Activity

(S)-(+)-Ibuprofen, a widely used nonsteroidal anti-inflammatory drug (NSAID), is primarily recognized for its analgesic, antipyretic, and anti-inflammatory properties. Its biological activity is largely attributed to its ability to inhibit cyclooxygenase (COX) enzymes, which play a crucial role in the synthesis of prostaglandins. This article explores the diverse biological activities of this compound, highlighting recent research findings, case studies, and metabolic pathways involved.

This compound exerts its therapeutic effects primarily through the inhibition of COX-1 and COX-2 enzymes, leading to a reduction in the production of pro-inflammatory prostaglandins. This inhibition not only alleviates pain and inflammation but also affects various physiological processes:

  • COX Inhibition : Both COX-1 and COX-2 are rate-determining enzymes in the synthesis of prostaglandins. Inhibition of these enzymes leads to decreased levels of pro-inflammatory mediators such as PGE2 and PGI2, which are implicated in pain signaling and inflammatory responses .
  • Metabolic Pathways : Recent studies have shown that this compound influences multiple metabolic pathways beyond COX inhibition. For example, it alters at least 34 different metabolic pathways in liver cells, including those involved in amino acid metabolism and oxidative stress responses .

1. Liver Enzyme Activity

Research has highlighted significant sex-related differences in the biological effects of this compound on liver enzyme activity:

  • Male vs. Female Responses : A study demonstrated that ibuprofen treatment caused marked differences in protein expression changes in male and female mice. For instance, it elevated cytochrome P450 activity in females while decreasing it in males, suggesting potential implications for drug metabolism and interactions .
  • Oxylipin Profiles : Ibuprofen treatment resulted in altered oxylipin profiles, indicating that it can influence lipid signaling pathways involved in inflammation .

2. Stem Cell Activity

High doses of this compound have been shown to enhance the biological activity of dental pulp stem cells (DPSCs):

  • Increased Cell Viability : Studies found that high-dose ibuprofen significantly improved cell viability and reduced DNA damage in DPSCs. This suggests that ibuprofen may enhance regenerative medicine applications by promoting stem cell proliferation and immunophenotype expression .

Case Study 1: Gender Differences in Drug Metabolism

A comprehensive study involving male and female mice illustrated how this compound affects liver metabolism differently based on sex. The findings revealed that:

  • Male mice exhibited an increase in specific liver enzymes associated with oxidative stress when treated with ibuprofen.
  • In contrast, female mice showed enhanced drug metabolism capabilities due to increased cytochrome P450 activity .

Case Study 2: Ibuprofen's Role in Regenerative Medicine

In a clinical context, researchers evaluated the effects of high-dose ibuprofen on DPSCs:

  • Results indicated a significant increase in mitotic activity and proliferation rates among DPSCs treated with ibuprofen compared to control groups.
  • These findings support the potential use of ibuprofen as an adjunct therapy in stem cell-based regenerative treatments .

Summary Table of Biological Activities

Biological ActivityMechanism/EffectReference
COX InhibitionReduces PGE2/PGI2 levels
Liver MetabolismAlters multiple metabolic pathways
Stem Cell ProliferationEnhances viability and reduces DNA damage

Properties

IUPAC Name

(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

InChI

InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

InChI Key

HEFNNWSXXWATRW-JTQLQIEISA-N
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

Canonical SMILES

CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

Isomeric SMILES

C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

Molecular Formula

C13H18O2
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

DSSTOX Substance ID

DTXSID9048724
Record name Dexibuprofen
Source EPA DSSTox
URL https://comptox.epa.gov/dashboard/DTXSID9048724
Description DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.

Molecular Weight

206.28 g/mol
Source PubChem
URL https://pubchem.ncbi.nlm.nih.gov
Description Data deposited in or computed by PubChem

Solubility

Insoluble
Record name Dexibuprofen
Source DrugBank
URL https://www.drugbank.ca/drugs/DB09213
Description The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.
Explanation Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)

CAS No.

51146-56-6
Record name (+)-Ibuprofen
Source CAS Common Chemistry
URL https://commonchemistry.cas.org/detail?cas_rn=51146-56-6
Description CAS Common Chemistry is an open community resource for accessing chemical information. Nearly 500,000 chemical substances from CAS REGISTRY cover areas of community interest, including common and frequently regulated chemicals, and those relevant to high school and undergraduate chemistry classes. This chemical information, curated by our expert scientists, is provided in alignment with our mission as a division of the American Chemical Society.
Explanation The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.
Record name Dexibuprofen [USAN:INN:BAN]
Source ChemIDplus
URL https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0051146566
Description ChemIDplus is a free, web search system that provides access to the structure and nomenclature authority files used for the identification of chemical substances cited in National Library of Medicine (NLM) databases, including the TOXNET system.
Record name Dexibuprofen
Source DrugBank
URL https://www.drugbank.ca/drugs/DB09213
Description The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.
Explanation Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)
Record name DEXIBUPROFEN
Source DTP/NCI
URL https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=759814
Description The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.
Explanation Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.
Record name Dexibuprofen
Source EPA DSSTox
URL https://comptox.epa.gov/dashboard/DTXSID9048724
Description DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.
Record name DEXIBUPROFEN
Source FDA Global Substance Registration System (GSRS)
URL https://gsrs.ncats.nih.gov/ginas/app/beta/substances/671DKG7P5S
Description The FDA Global Substance Registration System (GSRS) enables the efficient and accurate exchange of information on what substances are in regulated products. Instead of relying on names, which vary across regulatory domains, countries, and regions, the GSRS knowledge base makes it possible for substances to be defined by standardized, scientific descriptions.
Explanation Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.

Melting Point

49-53
Record name Dexibuprofen
Source DrugBank
URL https://www.drugbank.ca/drugs/DB09213
Description The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.
Explanation Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)

Synthesis routes and methods I

Procedure details

Surprisingly, only a few methods for a stereospecific chemical synthesis for 2-aryl-alkanoic acids, especially 2-aryl-propionic acids, are known. Piccolo et al. (J. Org. Chem. 50, 3945-3946, 1985) describe a stereospecific synthesis by the alkylation of benzene or isobutylbenzene with (S)-methyl-2-(chlorosulfonyl)-oxy or 2-(mesyloxy) propionate in the presence of aluminum chloride yielding (S)-methyl-2-phenyl-propionate in good chemical yield (50-80%) and excellent optical yield of >97% as determined by rotation through inversion of configuration at the attacking carbon atoms. The reaction conditions are very similar as described in some patents (Jpn. Kokai Tokkyo Koho 5808045; Chem. Abstracts, 1983, 98; 143138 k; Jpn. Kokai Tokkyo Koho 7979246; Chem. Abstracts, 1980, 92, 6253 f) where racemic reagents have been used. Extensions of this type of reactions to other aromatic substrates, e.g. toluene, isobutylbenzene, tetraline, anisole, naphthalene, 2-methoxy-naphthalene are described in Jpn. Kokai Tokkyo Koho 7971932; Chem. Abstracts 1979, 91, 20125 b; Jpn. Kokai Tokkyo Koho 78128327; Chem. Abstracts 1978, 89, 23975 y; Jpn. Kokai Tokkyo Koho 81145241; Chem. Abstracts 1982, 96, 68650 z; Jpn. Kokai Tokkyo Koho 78149945; Chem. Abstracts 1979, 90, 168303 h; Jpn. Kokai Tokkyo Koho 7844537; Chem. Abstracts 1978, 89, 108693 h; Jpn. Kokai Tokkyo 77131551; Chem. Abstracts 1978, 88, 104920 h. In a recent paper Piccolo et al. (J. Org. Chem. 52. 10, 1987) describe a synthesis leading to R-(-) ibuprofen, whereas Tsuchihashi et al. (Eur. Pat. Appl. EP 67,698, (1982); Chem. Abstracts 98, 178945 y, (1983) report a stereospecific synthesis of the R-(-) ibuprofen-methylester with excellent yields of about 75.0% and high optical purity (>95%) in contrast to Piccolo et al. (J. Org. Chem. 32, 10, 1987) having an optical purity of 15% only for the R-(-) ibuprofen. However, the same authors have reported chemical yields of 68% of S (+) ibuprofen having an optical purity of 75-78%, only. Hayashi, et al. (J. Org. Chem. 48, 2195, 1983; in: Asymmetric Reactions and Processes In Chemistry; eds E. L. Eliel and S. Otsuka, ACS-Symposium Ser. 1985, 1982, 177) describe a stereospecific synthesis of S-(+) ibuprofen through asymmetric Grignard cross-coupling which are catalyzed by chiral phosphine-nickel and phosphine-palladium complexes. The enantiomeric excess of the coupling products with various alkenyl halides under the influence of the above-mentioned metal phosphine complexes, including amino acids, depends strongly on the ligand and ranges up to 94% with enantiomeric excesses in the 60-70% range. A very useful ligand has been found in chiral 2-aminoalkyl phosphines achieving reasonable chemical yields and high optical purity. Furthermore, optically active 2-aryl-alkonates have been synthesized via a Friedel-Crafts synthesis by Sato and Murai (Jpn. Kokai Tokkyo Koho JP 61,210,049 t 86,210,049, 1986) yielding 46% S-(+) ibuprofen. Giordano et al. (EP application 0 158 913, 1985) have reported a process for the preparation of optically active 2-aryl-alkanoic acids and intermediates thereof by halogenation on the aliphatic carbon atom to the ketal group and rearrangements of the haloketals yielding pharmacologically active 2-aryl-alkanoic acids. A stereochemical synthesis of 2-aryl-propionic acids is described by Robertson et al. (EP application 0 205 215 A2, 1986) using 2-(R1)-alkane as the carbon source for the fungi Cordyceps in particular for Cordiceps militaris, yielding enantiomeric S-(+) products of high optical purity.
[Compound]
Name
aromatic substrates
Quantity
0 (± 1) mol
Type
reactant
Reaction Step One
Quantity
0 (± 1) mol
Type
solvent
Reaction Step Two
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Three
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Four
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Five
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Six
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Seven
[Compound]
Name
R-(-) ibuprofen
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Eight
[Compound]
Name
R-(-) ibuprofen-methylester
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Nine
[Compound]
Name
R-(-) ibuprofen
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Ten

Synthesis routes and methods II

Procedure details

To a solution of benzyl 2-p-isobutylphenylpropionate (3 g) in methylene chloride (18 ml) are added a solution of aluminum chloride (4 g) in nitromethane (50 ml) and anisole (3 ml) at 0° C., and the mixture is stirred at room temperature for 6 hours. The reaction mixture is diluted with ethyl acetate, washed with hydrochloric acid and water, dried and evaporated. The residue is recrystallized with n-hexane to give 2-p-isobutylphenylpropionic acid (186 mg) melting at 75°-77.5° C. Yield 91%.
Name
benzyl 2-p-isobutylphenylpropionate
Quantity
3 g
Type
reactant
Reaction Step One
Quantity
4 g
Type
reactant
Reaction Step One
Quantity
18 mL
Type
solvent
Reaction Step One
Quantity
50 mL
Type
solvent
Reaction Step One
Quantity
3 mL
Type
solvent
Reaction Step One
Quantity
0 (± 1) mol
Type
solvent
Reaction Step Two

Synthesis routes and methods III

Procedure details

Three grams of flurbiprofen and 30 g of poloxamer 237 were heated at 110° C. for 10 minutes to obtain a liquified mixture and cooled to 60° C. Into this mixture, 5 g of polyethylene glycol 300, 10 g of ethanol and 52 g of pH 4 buffer solution were added at 60° C. to obtain an ibuprofen gel.
Quantity
0 (± 1) mol
Type
reactant
Reaction Step One
[Compound]
Name
poloxamer 237
Quantity
30 g
Type
reactant
Reaction Step One
[Compound]
Name
polyethylene glycol 300
Quantity
5 g
Type
reactant
Reaction Step Two
[Compound]
Name
buffer solution
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Two
Quantity
10 g
Type
reactant
Reaction Step Two

Synthesis routes and methods IV

Procedure details

The process according to claim 1, wherein 3-isobutyl-cyclohexanone and sodium pyruvate are heated in a HCl and acetic acid solution to give a mixture of condensation products and said condensation products are heated for 4 to 5 hours with pyridine hydrochloride to give p-isobutylhydratropic acid.
Quantity
0 (± 1) mol
Type
reactant
Reaction Step One
Name
sodium pyruvate
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Two
Name
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Three
Quantity
0 (± 1) mol
Type
solvent
Reaction Step Three
Quantity
0 (± 1) mol
Type
reactant
Reaction Step Four

Retrosynthesis Analysis

AI-Powered Synthesis Planning: Our tool employs the Template_relevance Pistachio, Template_relevance Bkms_metabolic, Template_relevance Pistachio_ringbreaker, Template_relevance Reaxys, Template_relevance Reaxys_biocatalysis model, leveraging a vast database of chemical reactions to predict feasible synthetic routes.

One-Step Synthesis Focus: Specifically designed for one-step synthesis, it provides concise and direct routes for your target compounds, streamlining the synthesis process.

Accurate Predictions: Utilizing the extensive PISTACHIO, BKMS_METABOLIC, PISTACHIO_RINGBREAKER, REAXYS, REAXYS_BIOCATALYSIS database, our tool offers high-accuracy predictions, reflecting the latest in chemical research and data.

Strategy Settings

Precursor scoring Relevance Heuristic
Min. plausibility 0.01
Model Template_relevance
Template Set Pistachio/Bkms_metabolic/Pistachio_ringbreaker/Reaxys/Reaxys_biocatalysis
Top-N result to add to graph 6

Feasible Synthetic Routes

Reactant of Route 1
Reactant of Route 1
(S)-(+)-Ibuprofen
Reactant of Route 2
(S)-(+)-Ibuprofen
Reactant of Route 3
Reactant of Route 3
(S)-(+)-Ibuprofen
Reactant of Route 4
(S)-(+)-Ibuprofen
Reactant of Route 5
Reactant of Route 5
(S)-(+)-Ibuprofen
Reactant of Route 6
(S)-(+)-Ibuprofen

Disclaimer and Information on In-Vitro Research Products

Please be aware that all articles and product information presented on BenchChem are intended solely for informational purposes. The products available for purchase on BenchChem are specifically designed for in-vitro studies, which are conducted outside of living organisms. In-vitro studies, derived from the Latin term "in glass," involve experiments performed in controlled laboratory settings using cells or tissues. It is important to note that these products are not categorized as medicines or drugs, and they have not received approval from the FDA for the prevention, treatment, or cure of any medical condition, ailment, or disease. We must emphasize that any form of bodily introduction of these products into humans or animals is strictly prohibited by law. It is essential to adhere to these guidelines to ensure compliance with legal and ethical standards in research and experimentation.